Esra ADIŞEN, Ayla GÜLEKON, Mehmet Ali GÜRER

The clinical efficacy of topical calcipotriol and methylprednisolone aceponate in chronic plaque psoriasis

Amaç: Kronik plak psoriazis tedavisinde kalsipotriol ve metilprednizolon aseponat pomadın klinik etkinliklerini karşılaştırmak. Materyal ve Metod: Çalışmaya stabil ve kronik plak psoriazisi bulunan 30 hasta alındı. Olgular iki gruba ayrılarak kalsipotriol pomad ve metilprednizolon aseponat (MPA) tedavilerini günde iki kez 6 hafta süreyle kullandılar. İlaçların klinik etkinlikleri Psoriasis Area and Severity Index (PASI) Skoru kullanılarak değerlendirildi. Tedavi öncesi ve sonrası PASI skorları istatistiksel olarak karşılaştırıldı. Bulgular: Kalsipotriol grubunda tedavi öncesi PASI skoru ortalaması 9.98 ± 1.76 ve tedavi sonrası 3.04 ± 0.88 idi ve aradaki fark istatistiksel olarak anlamlıydı (p

Kronik plak psoriazisde topikal kalsipotriol ve metilprednizolon aseponatin klinik etkinlikleri

Purpose: To assess the clinical efficacy of calcipotriol and methylprednisolone aseponate ointments in the treatment of chronic plaque psoriasis. Methods: This study involved 30 patients with stable and moderate severity chronic plaque psoriasis. The patients were divided into 2 treatment groups and administered calcipotriol ointment or methylprednisolone aseponate (MPA) ointment twice daily for 6 weeks. The Psoriasis Area and Severity Index (PASI) scoring system was used for the clinical evaluation. Pre-treatment and post-treatment PASI scores were compared. Results: In the calcipotriol group, the mean of pre-treatment PASI scores was 9.98 ± 1.76 and the mean of post-treatment PASI scores was 3.04 ± 0.88. The difference was statistically significant (p

PDF

___

1. Christophers E, Mrowietz U. Psoriasis. In. Freedberg IM, Eisen AZ, Wolf K, Austen KF, Goldsmith AL, Katz IS, Fitzpatrick TB (eds): Fitzpatrick's Dermatology in General Medicine. 5th ed. New York: McGraw-Hill Inc; 1999. p. 495-521.
2. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology. Berlin: Springer; 2000.
3. Barker JNWN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001; 26: 321-325.
4. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
5. Farber EM. The language of psoriasis. Int J Dermatol 1991; 30: 295-302.
6. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CME. What is the role of topical calcipotriol in the treatment of mild-to-moderate chronic plaque psoriasis? BMJ 2000; 320: 963-967.
7. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 1994; 131: 514-520.
8. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001; 76: 943-949.
9. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris: Update and new strategies. Cutis 1999; 64: 315- 318.
10. Kecskes A, Mahn HD, Kuhlmann RK, Lange L. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity. J Am Acad Dermatol 1993; 29: 576-580.
11. Kecskes A, Jahn P, Wendt H, Lange L, Kuhlmann RK. Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers. Eur J Clin Pharmacol 1992; 43: 157-159.
12. Tauber U, Matthes H. Percutaneous absorption of methylprednisolone aceponate after single and multiple dermal application as ointment in male volunteers. Arzneimittel-Forschung 1992; 42: 1122-1124.
13. Koo JYM. Current consensus and update on psoriasis therapy: A perspective from the US. J Dermatol 1999; 26: 723-733.
14. Federman DG, Froelich CW, Kirsner RS. Topical psoriasis therapy. Am Fam Physician 1999; 15: 14-19.
15. Linden KG, Weinstein GD. Psoriasis: Current perspectives with an emphasis on treatment. Am J Med 1999; 107: 595-605.
16. Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA. Biologie effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28.
17. Van de Kerkhof PCM, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragbella K, Larsen FG, Munro CS, Tillman DM. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology 2002; 204: 214-221.
18. Bourke JF, Iqbal SJ, Hutchinson PE. Vitamin D analogues in psoriasis: effects on systemic calcium homeostasis. Br J Dermatol 1996; 135: 347-354.
19. Bagot M, Charue D, Lescs MC, Pamphile R, Revuz J. Immunosuppressive effects of 1,25-dihydroxyvitamin D3 and its analogue calcipotriol on epidermal cells. Br J Dermatol 1994; 130: 424-431.
20. Gianotti B, Carli P, Neri I. Treatment of psoriasis with calcipotriol; time of onset and healing of relapses. Eur J Dermatol 1997; 7: 275-278.
21. Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol 1999; 16: 321-325.
22. Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, Ruzicka T, Van De Kerkhof PC. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139: 649-654.
23. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131: 673-677.
24. Kaur I, Saraswat A, Kumar B. Comparison of calcipotriol and coal tar in conjunction with sun exposure in chronic plaque psoriasis: A pilot study. J Dermatol 2001; 28: 448- 450.
25. Jones BJ, Hutchinson PE. Vitamin D analogues and psoriasis. Br J Dermatol 1992; 127: 71-78.
26. Jain S, Sehgal VN. Psoriasis and calcipotriol: an overview. Int J Dermatol 1997; 36: 255-258.
27. Fogh K, Kragbella K. Vitamin D3 analogues. Clin Dermatol 1997; 15: 705-713.
28. Bourke JF, Mumford R, Whittaker P, Iqbal SJ, Le Van LW, Trevellyan A, Hutchinson PE. The effects of topical calcipotriol on systemic calcium homeostatis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997; 37: 929-934.
29. Marks R, Barton SP. Assessment of disease progress in psoriasis. Arch Dermatol 1989; 125: 235-240.
30. Van Steensel MAM, Steijlen PM. Genetics of psoriasis. Clin Dermatol 1997; 15: 669-675.
31. Brown AJ.Therapeutic uses of vitamin D analogues. Am J Kidney Dis 2001; 38: S3-S19.
32. Savoia P, De Matteis A, Bernengo MG. Effects of topical calcipotriol on expression of adhesion molecules in psoriasis. J Cutan Pathol 1998; 25: 89-94.
33. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby J. A new Calcipotriol/Betamethasone formulation with rapid onset of action was superior to monotherapy with Betamethasone dipropionate or Calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-135.
34. Van Rossum MM, Van Erp PEJ, Van de Kerkhof PCM. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: A flow cytometric study. Dermatology 2001; 203: 148-152.
35. Tüzün B, Tüzün Y. Psoriasis Dipnotları. Istanbul: Nobel Tip Kitabevi; 1998.
36. Koo JYM, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.